Agenus generates fluctuating annual revenues derived primarily through corporate collaboration agreements, licensing fees, research and development milestones, and commercial product royalties. Recent financial reports indicate trailing twelve-month revenues hovering around $132.7 million, with annual revenues for the preceding fiscal year closing at approximately $114.2 million, reflecting steady contract inflows from bio-pharma partners supporting its immunotherapy co-development pipelines.